NYSE:TEVAPharmaceuticals
A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress
Why Teva’s latest earnings are back in focus
Teva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income and operating income, provided fresh biosimilar updates, and highlighted stronger UZEDY sales alongside a new schizophrenia NDA filing.
See our latest analysis for Teva Pharmaceutical Industries.
The strong first quarter update, FDA progress for biosimilars, and Emalex deal have come alongside sharp gains,...